Skip to main content

N-SIDE welcomes Wade Wirta as US Managing Director

Published on: 10 Oct 2019

Louvain-la-Neuve, Belgium, 9th October 2019 / Sciad Newswire / N-SIDE, a global software consulting company specializing in advanced analytics technologies, is pleased to welcome Wade Wirta as US Managing 
Director.

Wade has over 25 years of experience working in the pharmaceutical industry, with an extensive background in clinical trial supply and optimization. In his new role, Wade will be developing the US market for N-SIDE and accelerating the growth of their new N-SIDE Suite for Clinical Trials. N-SIDE provides the only end-to-end clinical trial supply chain management solution offering global, risk-based optimization. This cutting edge, cloud-based platform enables the pharmaceutical and biotech industry to future-proof clinical trial supply chain management whilst minimizing costs, drug waste and risk. The N-SIDE Suite provides an unprecedented level of transparency that enables proactive risk management, leading to significant increases in clinical trial efficiency.  

Wade Wirta said, “N-SIDE has an industry first offering for the US clinical trial sector, providing a solution to the complex challenges faced by drug companies who are under rising pressure to improve efficiency while maintaining high levels of service for patients. N-SIDE is changing the paradigm on clinical trial supply chain management - from a historically reactive inefficient function to an integrated value add competitive differentiator for our sponsors and clients. I’m excited to be a part of this forward-thinking organization. I look forward to working with the industry to adopt this transformational approach to trial supply chain management that will benefit our sponsors and clients, but more importantly will benefit patients seeking life-changing therapies.”

Jacques Parlongue, N-SIDE CEO, commented, “We are delighted to welcome Wade into our team. The continuation and extension of our development in the US represents a turning point for N-SIDE, thanks to an annual growth rate exceeding 100%.”
 

Related articles

European Commission Approves Pfizer’s EMBLAVEO® fo

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Rilzabrutinib LUNA 3 phase 3 study met primary end

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Bristol Myers Squibb and Cellares Announce a $380M

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster